CKS1B and bone marrow disorder: These phenotypes point to CKS1 and CKS2 as actionable targets in bone marrow disorders where protein quality control and intracellular signaling declines or is hijacked by neoplastic mutations, and indeed we have already demonstrated that inhibition of CKS1 can be “chemoprotective” for healthy HSCs.21